Cytokinetics Stock Performance
| CYTK Stock | USD 49.10 1.43 3.00% |
The firm shows a Beta (market volatility) of 1.69, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytokinetics will likely underperform. At this point, Cytokinetics has a negative expected return of -0.2%. Please make sure to confirm Cytokinetics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Cytokinetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cytokinetics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 2.61 | Five Day Return (11.29) | Year To Date Return (41.85) | Ten Year Return 1 K | All Time Return (49.36) |
Last Split Factor 1:6 | Last Split Date 2013-06-25 |
1 | Acquisition by Pletcher Brett A of 33140 shares of Cytokinetics subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 6.67 subject to Rule 16b-3 | 09/03/2024 |
3 | Disposition of 5422 shares by Malik Fady Ibraham of Cytokinetics at 53.05 subject to Rule 16b-3 | 09/13/2024 |
4 | Insider Sale EVP Research Development Fady Malik Sells 7,300 Shares of Cytokinetics Inc ... | 09/18/2024 |
5 | Disposition of 11500 shares by Robert Blum of Cytokinetics at 59.49 subject to Rule 16b-3 | 10/11/2024 |
6 | Disposition of 5300 shares by Malik Fady Ibraham of Cytokinetics at 7.96 subject to Rule 16b-3 | 10/15/2024 |
7 | Disposition of 4452 shares by Wierenga Wendall of Cytokinetics at 7.37 subject to Rule 16b-3 | 10/28/2024 |
8 | Cytokinetics Reports Q3 Loss, Lags Revenue Estimates | 11/06/2024 |
9 | Cytokinetics Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid Financial ... | 11/07/2024 |
10 | Cytokinetics Third Quarter 2024 Earnings Misses Expectations | 11/08/2024 |
11 | Cytokinetics Coverage Initiated by Analysts at Royal Bank of Canada | 11/11/2024 |
12 | FMR LLC Bolsters Stake in Cytokinetics Inc | 11/13/2024 |
13 | ADAR1 Capital Management, LLC Expands Stake in Cellectar Biosciences Inc | 11/15/2024 |
14 | Goldman Sachs maintains Neutral on Cytokinetics, 60 target | 11/19/2024 |
15 | Why Is Cytokinetics, Incorporated Among the Worst Performing Biotech Stocks in 2024 - Yahoo Finance | 11/21/2024 |
| Begin Period Cash Flow | 67.2 M |
Cytokinetics |
Cytokinetics Relative Risk vs. Return Landscape
If you would invest 5,707 in Cytokinetics on August 24, 2024 and sell it today you would lose (797.00) from holding Cytokinetics or give up 13.97% of portfolio value over 90 days. Cytokinetics is currently does not generate positive expected returns and assumes 2.5218% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Cytokinetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytokinetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytokinetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytokinetics, and traders can use it to determine the average amount a Cytokinetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0806
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYTK |
Estimated Market Risk
| 2.52 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cytokinetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytokinetics by adding Cytokinetics to a well-diversified portfolio.
Cytokinetics Fundamentals Growth
Cytokinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Cytokinetics, and Cytokinetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytokinetics Stock performance.
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (304.11) % | ||||
| Current Valuation | 5.66 B | ||||
| Shares Outstanding | 118.01 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 60.31 X | ||||
| Price To Sales | 1,748 X | ||||
| Revenue | 7.53 M | ||||
| Gross Profit | (146.22 M) | ||||
| EBITDA | (456.68 M) | ||||
| Net Income | (526.24 M) | ||||
| Cash And Equivalents | 586.03 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 755.77 M | ||||
| Debt To Equity | 2.93 % | ||||
| Current Ratio | 9.01 X | ||||
| Book Value Per Share | (0.12) X | ||||
| Cash Flow From Operations | (414.33 M) | ||||
| Earnings Per Share | (5.38) X | ||||
| Market Capitalization | 5.63 B | ||||
| Total Asset | 824.32 M | ||||
| Retained Earnings | (2.11 B) | ||||
| Working Capital | 525.37 M | ||||
| Current Asset | 113.11 M | ||||
| Current Liabilities | 31.65 M | ||||
About Cytokinetics Performance
By examining Cytokinetics' fundamental ratios, stakeholders can obtain critical insights into Cytokinetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cytokinetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (0.26) | (0.27) | |
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.69) | (0.65) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | 1.36 | 1.43 |
Things to note about Cytokinetics performance evaluation
Checking the ongoing alerts about Cytokinetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytokinetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytokinetics generated a negative expected return over the last 90 days | |
| Cytokinetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.53 M. Net Loss for the year was (526.24 M) with loss before overhead, payroll, taxes, and interest of (146.22 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (414.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Cytokinetics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Why Is Cytokinetics, Incorporated Among the Worst Performing Biotech Stocks in 2024 - Yahoo Finance |
- Analyzing Cytokinetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytokinetics' stock is overvalued or undervalued compared to its peers.
- Examining Cytokinetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytokinetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytokinetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytokinetics' stock. These opinions can provide insight into Cytokinetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.